38263569|t|Lecanemab-irmb (Leqembi ) for Treatment of Alzheimer's Disease.
38263569|a|Lecanemab-irmb (Leqembi ) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease (AD). AD is an irreversible and progressive neurodegenerative disorder affecting more than 6.5 million Americans 65 years of age and older and it is projected to rise to 14 million by 2060. As the disease progresses, it deteriorates short-term memory and thinking skills and, eventually, the ability to perform simple tasks of daily living. The cost of care for AD patients in the United States is estimated at more than $183 billion every year.
38263569	0	9	Lecanemab	Chemical	MESH:C000612089
38263569	43	62	Alzheimer's Disease	Disease	MESH:D000544
38263569	96	108	amyloid beta	Gene	351
38263569	158	177	Alzheimer's disease	Disease	MESH:D000544
38263569	179	181	AD	Disease	MESH:D000544
38263569	184	186	AD	Disease	MESH:D000544
38263569	222	248	neurodegenerative disorder	Disease	MESH:D019636
38263569	540	542	AD	Disease	MESH:D000544
38263569	543	551	patients	Species	9606
38263569	Negative_Correlation	MESH:C000612089	MESH:D000544
38263569	Association	MESH:D000544	351

